Dr. David Vocadlo is a Tier I Canada Research Chair in Chemical Biology and professor in the Departments of Chemistry and Molecular Biology and Biochemistry at Simon Fraser University (SFU). Vocadlo leads an interdisciplinary research team with a focus on improving understanding about how specific glycan structures influence cell function, with particular emphasis on their roles in neurodegenerative diseases. Both the fundamental and translational research from his laboratory have attracted major industrial interest.
His research has been recognized with awards including the Horace S. Isbell Award of the American Chemical Society, and an E.W.R. Steacie Fellowship from the Natural Sciences and Engineering Council of Canada. He was named one of Canada’s Top 40 Under 40, and one of the inaugural members of the Royal Society of Canada’s College of New Scholars, Artists and Scientists. He is also a co-founder of Alectos Therapeutics, which partnered with Merck to develop compounds to combat neurodegenerative diseases.
He holds a PhD from the University of British Columbia, and completed his postdoctoral training at the University of California at Berkeley.
University: Simon Fraser University
Department: Chemistry; Molecular Biology and Biochemistry